←Back to Expert Scholars
Translational Medicine / 转化医学LAG-3, PD-L1 Discovery
Gordon Freeman
PhD
🏢Dana-Farber Cancer Institute🌐USA
Professor of Medicine
145
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Gordon Freeman co-discovered PD-L1 and PD-L2 and has driven mechanistic understanding of checkpoint pathways including LAG-3. His work underlies the clinical success of nivolumab/relatlimab LAG-3 + PD-1 combination that is being investigated to rescue checkpoint-resistant cold tumors.
Share:
🧪Research Fields 研究领域
LAG-3
PD-L1
PD-1 pathway
checkpoint discovery
dual checkpoint blockade
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Gordon Freeman 的研究动态
Follow Gordon Freeman's research updates
留下邮箱，当我们发布与 Gordon Freeman（Dana-Farber Cancer Institute）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment